Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial
Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.
• Participants voluntarily provided written informed consent for this trial;
• Aged 18 to 80 years, inclusive, regardless of gender;
• With stable vital signs;
• Diagnosis of SBS-IF, confirmed by existing medical/surgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\<200 cm from the duodenojejunal flexure), and meeting one of the following criteria:
⁃ Colon continuity maintained without jejunal/ileal stoma (Type II or III);
‣ Presence of a jejunostomy or ileostomy (Type I);
• Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;
• Ability to comply with the medication dosing and visit schedule;
• Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;
• No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;
• No history of drug abuse;
• Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);
• No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.